Patients describe it as localized or generalized skin sensitivity rather than true urticaria
Conversely, low-dose GLP-1 therapy is not appropriate for patients without established indications, particularly those seeking anti-inflammatory effects alone without diabetes or obesity
ProHealth positions BPC-157 as a dietary supplement complying with current regulations, but regulatory landscapes evolve
Pharmacological Treatment of Obesity: A Review (2011)
The FDA prescribing information for Vyleesi provides clinicians and patients with precisely characterized cardiovascular effects (peak systolic elevation of ~6 mmHg at 24 hours post-dose, returning to baseline within 12 hours), documented contraindications (uncontrolled hypertension, known cardiovascular disease), and management strategies for nausea (ondansetron 30 minutes pre-dose)
He added that "no one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients." The FDA's announcement comes just months after the agency declared the shortage of tirzepatide the active ingredient in Eli Lilly's weight loss injection Zepbound and diabetes counterpart Mounjaro was over